ClinicalTrials.gg
Not yet recruitingNCT07876206Updated Oct 20, 2026

Pilot Trial of a Meaning And Problem-Solving (MAPS) Intervention for Family Caregivers of Children With Medical Complexity

An interventional study of MAPS (Meaning And Problem Solving) and Usual Psychosocial Care in Family Caregivers and Children With Medical Complexity (CMC), sponsored by University of Pittsburgh. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Supportive care

Updated Oct 15, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate a new program specifically developed to better support parents and family caregivers of children with complex health needs. The name of this program is MAPS (Meaning and Problem Solving). The goal of MAPS is to improve caregivers' emotional well-being and confidence in dealing with adversity. The investigators are testing the program to see if parent and family caregiver participants find the MAPS program acceptable and to identify ways the investigators can improve it.

Read the detailed description

The goal of this pilot study is to evaluate whether conducting a randomized clinical trial of a novel psychological intervention, entitled MAPS, specifically designed for family caregivers of children with medical complexity, is feasible and acceptable. The investigators will compare participation in the MAPS program to usual psychosocial care. Family caregiver participants randomized to the MAPS intervention will participate in 8 one-on-one virtual sessions with a trained MAPS facilitator over 2-3 months, and complete a pre- and post-intervention survey questionnaire, as well as an exit interview.

02

Conditions studied

  • Family Caregivers
  • Children With Medical Complexity (CMC)
03

In context

Lead sponsor

University of Pittsburgh is the lead sponsor of 1,414 studies on the registry; 168 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Family caregiver of a child or dependent adult with impaired capacity receiving medical care at UPMC Children's Hospital of Pittsburgh's Complex Care Center or from UPMC Children's Hospital of Pittsburgh's Supportive Care team.
  2. Caregiver has medical decision-making authority for their child (as determined by the clinical attending physician).
  3. Caregiver's child is medically complex, which is defined as 1+ chronic health conditions, major functional limitations, significant health service needs, and high health care utilization.

Exclusion criteria

Exclusion Criteria:

  1. Caregiver is \<18 years of age.
  2. Caregiver does not have medical decision-making authority (e.g., grandparent accompanying child to appointment).
  3. Caregiver unable to complete intervention sessions in English.
  4. Caregivers of children who do not live at home (i.e., reside in long-term nursing care facilities).
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    MAPS Intervention

    Participants randomized to this experimental arm will undergo 8 one-on-one sessions with a trained MAPS interventionist over 2-3 months. Sessions can be conducted in-person or via videoconference (per participant preference); and will last 45- to 60-minutes in duration.

    Behavioral: MAPS (Meaning And Problem Solving)

  • Active comparator
    Usual Psychosocial Care

    Participants randomized to the comparison arm will receive usual psychosocial care services routinely provided by our institution's pediatric complex care and palliative care interdisciplinary team. This psychosocial care includes routine clinical evaluations, emotional and social support, and care coordination services, which are delivered via scheduled outpatient clinic visits, phone/virtual consultations, or inpatient visits.

    Behavioral: Usual Psychosocial Care

Interventions

  • BehavioralMAPS (Meaning And Problem Solving)

    The MAPS intervention is a manualized behavioral program, tailored for family caregivers of children with medical complexity, which consists of 8 one-on-one 45-60 minute sessions delivered by a trained interventionist. The intervention aims to improve participant mental health and emotional well-being by enhancing participants' sense of meaning and problem-solving skills. Key components adapted from meaning-centered psychotherapy include: identifying sources of meaning, guided imagery, personalized coping statements, meaningful activity scheduling, and values-based goal setting. Problem-solving skills-training is adapted from Bright IDEAS, a 5-step framework to teach problem-solving skills originally developed for mothers of children with cancer. Participants receive a workbook with reference materials, worksheets, and home practice exercises to promote skill mastery and routine maintenance.

  • BehavioralUsual Psychosocial Care

    Participants randomized to the comparison arm will receive usual psychosocial care services routinely provided by our institution's pediatric complex care and palliative care interdisciplinary team. This psychosocial care includes routine clinical evaluations, emotional and social support, and care coordination services, which are delivered via scheduled outpatient clinic visits, phone/virtual consultations, or inpatient visits.

06

What researchers measure

Primary outcomes

  1. Feasibility: Recruitment Rate

    Percentage of eligible caregivers approached who consent to participate, and percentage of consented participants who are successfully enrolled.

    Time frame: Approach-to-Consent: from initial approach to 12 weeks after initial approach. Consent-to-Enroll: 12 weeks from obtaining written informed consent .

  2. Feasibility: Retention Rate

    Percentage of randomized participants who complete the study protocol.

    Time frame: From study enrollment to 12-weeks post-enrollment

  3. Feasibility: Data Collection Completion Rate

    Percentage of required participant-reported outcome assessments successfully completed across all study time points.

    Time frame: From study enrollment to 12-weeks post-enrollment

  4. Feasibility: Intervention Session Completion

    Percentage of planned intervention sessions completed by end of trial.

    Time frame: From study enrollment to 12-weeks post-enrollment

  5. Feasibility: Intervention Fidelity

    Adherence of interventionists to protocol content, delivery, and procedures, evaluated using an intervention fidelity scoring matrix. For all intervention sessions, this matrix assesses the following domains: rapport building, professionalism, flexibility, engagement, protocol application, and pacing. Each domain is assessed on a 5-point Likert scale (Poor \[1\] to Excellent \[5\]). Additionally, each session will be assessed for delivery of session-specific content (e.g., "discussing concept of meaning"), also using a 5-point Likert scale. Session intervention fidelity will be calculated by averaging rating for each element; higher scores represent higher intervention fidelity.

    Time frame: From study enrollment to 12-weeks post-enrollment

  6. Intervention and Trial Protocol Acceptability

    Percentage of participants reporting high acceptability ("agree" or "completely agree") to participating in the intervention and trial protocol on post-study exit questionnaire.

    Time frame: From study enrollment to 12-weeks post-enrollment

  7. Satisfaction with Intervention

    Percentage of participants reporting high satisfaction ("satisfied" or "very satisfied") in the experiences with the MAPS intervention in post-study evaluation questionnaire.

    Time frame: From study enrollment to 12-weeks post-enrollment.

Secondary outcomes

  1. Change in Meaning-Focused Coping (PROMIS Item Bank v1.0 - Meaning and Purpose - Short Form 8a)

    Assessed using the 8-item PROMIS Meaning and Purpose Short Form. Items evaluate self-reported sense of life direction, purpose, and value on a 5-point Likert scale (1 = "Not at all" to 5 = "Very much"). Item scores are summed and converted to a standardized T-score (mean = 50, SD = 10; typical range: 24.3 to 68.2). Higher T-scores indicate a higher sense of meaning and purpose.

    Time frame: Baseline and 12-weeks post-enrollment

  2. PROMIS General Self-Efficacy

    Assessed using the PROMIS General Self-Efficacy scale. Items evaluate a person's general confidence in their ability to carry out tasks and reach goals. Items are scored on a 5-point Likert scale and converted to a standardized T-score (mean = 50, standard deviation = 10; typical range approximately 20 to 80). Higher T-scores reflect greater general self-efficacy.

    Time frame: Baseline and 12-weeks post-enrollment

  3. Change in Emotional Regulation Self-Efficacy (PROMIS Item Bank v1.0 - Self-Efficacy for Managing Emotions - Short Form 8a)

    Assessed using the 8-item PROMIS Self-Efficacy for Managing Emotions Short Form. Items evaluate confidence in managing difficult emotional states on a 5-point Likert scale (1 = "I am not at all confident" to 5 = "I am very confident"). Item scores are summed and converted to a standardized T-score (mean = 50, SD = 10; typical range: 25.8 to 64.2). Higher T-scores represent greater self-efficacy for emotional regulation.

    Time frame: Baseline and 12-weeks post-enrollment

  4. Change in Positive Affect (PROMIS Positive Affect Short Form)

    Assessed using the PROMIS Positive Affect Short Form (15 items). Items evaluate feelings of happiness, joy, and positive emotional states over the past 7 days on a 5-point Likert scale. Scores are converted to a standardized T-score (mean = 50, standard deviation = 10; range approximately 20 to 80). Higher T-scores indicate higher levels of positive affect.

    Time frame: Baseline and 12-weeks post-enrollment

  5. Change in Emotional Distress (PROMIS Anxiety, Depression, and Anger Short Forms)

    Assessed using the PROMIS Anxiety Short Form (8 items), PROMIS Depression Short Form (8 items) and PROMIS Anger Short Form (5 items). Items evaluate self-reported symptoms over the past 7 days on a 5-point Likert scale. Each domain generates a separate standardized T-score (mean = 50, standard deviation = 10; range approximately 20 to 80). Higher T-scores indicate higher levels of anxiety, depression, and anger (greater emotional distress).

    Time frame: Baseline and 12-weeks post-enrollment

  6. Change in Emotional Support (PROMIS Item Bank v2.0 - Emotional Support - Short Form 8a)

    Assessed using the 8-item PROMIS Emotional Support Short Form. Items evaluate perceived feelings of being cared for and having someone to listen to or confide in on a 5-point Likert scale (1 = "Never" to 5 = "Always"). Raw scores are converted to a standardized T-score (mean = 50, SD = 10; typical range: 25.3 to 63.8). Higher T-scores indicate higher levels of perceived emotional support.

    Time frame: Baseline and 12-weeks post-enrollment

  7. Change in Global Health (PROMIS Scale v1.2 - Global Health)

    Assessed using the 10-item PROMIS Global Health scale. Items evaluate overall perceptions of general health, physical health, mental health, quality of life, social activities, and pain/fatigue on 5-point Likert scales. Items are summarized into two primary domain subscales: Global Physical Health (GPH) and Global Mental Health (GMH). Raw subscale scores are converted to standardized T-scores (mean = 50, SD = 10; range: 16.2 to 67.7). Higher T-scores indicate better health functioning.

    Time frame: Baseline and 12-weeks post-enrollment

  8. Change in Child Global Health (PROMIS Early Childhood Global Health)

    Assessed using the parent-proxy PROMIS Early Childhood Global Health Module (8 items). Evaluates the child's overall physical, mental, and social health status on a 5-point scale. Raw scores are converted to a standardized T-score (mean = 50, SD = 10; range: approx. 16.2 to 66.8). Higher T-scores represent better overall child health status.

    Time frame: Baseline and 12-weeks post-enrollment

  9. Change in Spiritual Well-Being (FACIT-Sp-12)

    Assessed using the 12-item Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being Scale (FACIT-Sp-12). Items evaluate spiritual well-being across two main domains (Meaning/Peace and Faith) or three subdomains (Meaning, Peace, and Faith) on a 5-point Likert scale (0 = "Not at all" to 4 = "Very much"). Total scores range from 0 to 48, with higher scores indicating greater spiritual well-being and a stronger sense of meaning, peace, and faith.

    Time frame: Baseline and 12-weeks post-enrollment

  10. Change in Social Problem-Solving Ability (SPSI-R:SF)

    Assessed using the 25-item Social Problem-Solving Inventory-Revised Short Form (SPSI-R:SF). Items evaluate real-world problem-solving attitudes and skills across 5 subscales: Positive Problem Orientation (PPO), Negative Problem Orientation (NPO), Rational Problem Solving (RPS), Impulsivity/Carelessness Style (ICS), and Avoidance Style (AS). Items are scored on a 5-point Likert scale (0 = "Not at all true of me" to 4 = "Extremely true of me"). Standardized total scores range from 0 to 20 (or converted standard scores with a mean of 100, SD = 15), with higher total scores reflecting more constructive and effective social problem-solving abilities.

    Time frame: Baseline and 12-weeks post-enrollment

  11. Change in Child Symptom Experience (Memorial Symptom Assessment Scale)

    Assessed using the Memorial Symptom Assessment Scale (MSAS) parent-proxy scale (20 items). Evaluates the frequency, severity, and distress associated with common physical and psychological symptoms. Symptom items are scored on multi-point Likert scales to yield subscale scores and a Total MSAS Score ranging from 0 to 100, where higher scores represent greater symptom frequency, severity, and distress.

    Time frame: Baseline to 12-weeks post-enrollment

Other outcomes

  1. Change in child acute health care utilization

    Assessed using electronic health record (EHR)-extracted healthcare utilization count data. We will track the total count of acute and routine healthcare service encounters, including emergency department (ED) visits, inpatient hospital admissions, and outpatient clinic appointments. Comparison evaluates the difference in encounter counts per participant between the 3-month pre-enrollment period and the 3-month post-enrollment period.

    Time frame: 3 months prior to study enrollment and 3 months post-enrollment

07

Study locations

1 site
  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
08

References and documents

Individual participant data

Plan to share: Yes — All de-identified individual participant data, along with the study protocol and statistical analysis plan, will be available to qualified researchers upon reasonable request and creation of a data sharing agreement. Data will be made available following the publication of primary study results.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 3 months after publication of results and up to 5 years after publication of results.

Access criteria: Access to de-identified participant data, study protocol, and statistical analysis plan will be granted to scientific researchers who provide a methodologically sound research proposal. Requests must be sent to the Principal Investigator for review and approval. Data release is contingent upon creation of a formal data sharing agreement (DSA) to ensure participant confidentiality and data security.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2026
First posted
Oct 15, 2026
StartEst.
Jan 2027
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 15, 2026
Show all 2 updates
  1. Oct 20, 2026
    Minor edits only
    + 2 other changes: description and design details
  2. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07876206
Responsible party
Justin Yu (Assistant Professor, University of Pittsburgh) — Principal investigator
First posted
Oct 15, 2026
Start date
Jan 2027 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 20, 2026

Study contacts

Justin A Yu, MD, MSc
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion